 Report WHO informal consultation preclinical clinical aspects use immunomodulators HIV infection Geneva April World Health Organization Global Programme AIDS wide spectrum immunomodulatory strategies promise people HIV infection numerous gaps understanding normal regulation immune system progression HIV infection Preclinical development immunomodulators strong rationale use substance appropriate laboratory studies vitro vivo Preclinical studies safety therapeutic agent assessment potential adverse effects immune function virus replication therapeutic modalities preclinical level Clinical evaluations strong rationale safety concerns Initial studies patients intermediate stage HIV disease progression Immunomodulators unusual dose-response patterns trials consultation WHO forum timely exchange validation information development clinical evaluation immunomodulators treatment individuals HIV